PI-RADS

PI-RADS condenses the multiparametric MRI read into a single ordered score from 1 to 5 that broadly expresses how likely a lesion is to be clinically significant prostate cancer — low numbers meaning improbable, high numbers meaning probable. Crucially, the scoring is zone-aware: a 'dominant' sequence drives the assessment depending on whether the lesion sits in the peripheral or transition zone, with the other sequences playing supporting or tie-breaking roles. The system also standardizes how the MRI should be acquired and how the report is structured. Consult the official ACR/ESUR PI-RADS v2.1 document for the exact scoring criteria and thresholds.

• 1 — Very lowClinically significant cancer is highly unlikely.
• 2 — LowClinically significant cancer is unlikely.
• 3 — Intermediate / equivocalGenuinely uncertain — the hard-to-call middle ground.
• 4 — HighClinically significant cancer is likely.
• 5 — Very highClinically significant cancer is highly likely, often with larger size or extracapsular features.

These are our plain-language summaries. For the exact criteria, thresholds, and management rules, see the official source.

PI-RADS is the prostate-MRI analogue of BI-RADS and the dominant standardized scheme, but it isn't the only approach: many centers also use Likert scoring, which lets the reader fold in clinical context (PSA, prior history) and weigh all sequences more flexibly, and which sometimes shows higher specificity in head-to-head work. Compared with its own past, today's PI-RADS abandoned v1's additive scoring in favor of the v2 dominant-sequence model, then fine-tuned it in v2.1. As of mid-2026 there is open disagreement about whether a version 3 is warranted: proponents point to the weakly performing transition-zone pathway and to category labels that don't match observed cancer prevalence, while others argue the evidence base isn't yet mature enough to justify another revision.

A large 2024 systematic review and meta-analysis found PI-RADS v2.1 highly sensitive but only moderately specific for clinically significant cancer, with per-category cancer rates climbing steeply across the 1–5 scale. Reproducibility is moderate and experience-dependent, with pooled inter-reader agreement around kappa 0.6 and little measurable improvement from v2 to v2.1. PI-RADS is now embedded in major guidelines and routine practice for biopsy decision-making, but documented limitations include low specificity (driving false positives), the management dilemma of equivocal category 3 lesions, and unvalidated transition-zone rules — shortcomings that frame the current debate over whether to revise the system.

What does a PI-RADS score mean?

It's a 1-to-5 estimate of how likely a prostate MRI lesion is to be clinically significant cancer — 1 is very unlikely, 5 is very likely — used to guide whether a biopsy is needed.

Does PI-RADS 3 mean I need a biopsy?

Category 3 is the equivocal middle ground, and the most debated. Whether to biopsy often depends on other factors (PSA density, prior biopsy, patient preference) rather than the score alone.

Is there a PI-RADS 6 like BI-RADS?

No. PI-RADS uses a 1-to-5 scale only; it does not have a 'biopsy-proven cancer' category the way BI-RADS does.

What's the current version, and is a version 3 coming?

The current version is v2.1, from 2019. There is active debate about a possible version 3, but as of mid-2026 none has been released.

How is PI-RADS different from a Likert score?

PI-RADS follows fixed, zone-specific rules and largely ignores clinical data when scoring; Likert lets the radiologist incorporate clinical context and judgment, which can change specificity.

mpMRI (multiparametric MRI)

Prostate MRI combining T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences.

csPCa (clinically significant prostate cancer)

Cancer aggressive enough to matter clinically (typically Grade Group 2 or higher); what PI-RADS is designed to flag.

DWI / ADC

Diffusion-weighted imaging and its apparent diffusion coefficient map; the dominant sequence for peripheral-zone scoring.

DCE

Dynamic contrast-enhanced imaging; a supporting sequence used mainly to upgrade certain peripheral-zone lesions.

Peripheral zone / transition zone

The two main prostate regions PI-RADS scores differently, each with its own 'dominant' sequence.

Dominant sequence

The MRI sequence that primarily determines the score in a given zone (DWI in PZ, T2W in TZ).

ESUR / AdMeTech

The European Society of Urogenital Radiology and the AdMeTech Foundation — co-developers of PI-RADS alongside the ACR.

• officialACR PI-RADS official page
• referenceRadiology Assistant — Prostate Cancer PI-RADS v2.1
• referencePI-RADS v2.1 diagnostic-performance meta-analysis (Radiology 2024)
• calculatorPI-RADS v2.1 calculator (third-party, link-only)